Jonathan Weber is the Jefferiss Professor of Communicable Diseases and GU Medicine, and the Director of Research for the Faculty of Medicine at Imperial College London. He is based at the St Mary’s Hospital campus, within the Wright-Fleming Institute. He is a clinician by training, and has undertaken extensive clinical and laboratory based research on HIV/AIDS, HTLV-I and other STIs. After general medical training he was a Wellcome Clinical Training Fellow at St Mary’s Hospital Medical School (1982-5), subsequently a Wellcome Trust Lecturer in Cell and Molecular Biology at the Institute for Cancer Research Chester Beatty Labs, and then Senior Lecturer in Infectious Diseases at the Royal Postgraduate Medical School, Hammersmith Hospital (1988-1991). He was appointed to his current position at Imperial College in 1990, in order to establish a new academic department studying HIV and other STIs.
Jonathan Weber’s work on HIV infection commenced in 1982, when he established the first UK cohort studies of the natural history of AIDS at St Mary’s Hospital, together with Tony Pinching. He then trained in laboratory retrovirology under Prof Robin Weiss FRS before establishing his own laboratory and clinical investigation centre. His work began with clinical epidemiology and natural history studies, then fundamental research on humoral immunity in HIV infection and viral tropism, and then to early phase clinical investigation of the emerging antiretroviral drugs, potential HIV vaccines and latterly vaginal microbicides.
Jonathan Weber was founding editor of the journal “AIDS” 1987-1992, the leading specialist journal in the field. He co-founded the WHO Network for HIV characterisation in 1992, and advises WHO, UNAIDS, DfID and EC on aspects of HIV infection. He has published over 200 scientific papers on the clinical, epidemiological and virological aspects of HIV infection and other STIs.
- Audio recording taken from the BBC Radio 4 Today website
et al., 2010, PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial, The Lancet, Vol:376, ISSN:0140-6736, Pages:1329-1337
et al., 2013, Short-Course Antiretroviral Therapy in Primary HIV Infection, New England Journal of Medicine, Vol:368, ISSN:0028-4793, Pages:207-217
et al., 2008, EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone, Vaccine, Vol:26, ISSN:0264-410X, Pages:3162-3174
et al., 2009, Adaptation of HIV-1 to human leukocyte antigen class I, Nature, Vol:458, ISSN:0028-0836, Pages:641-U108
et al., 2010, B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection, Nature Communications, Vol:1, ISSN:2041-1723, Pages:102-102
et al., 2008, An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses, Journal of Experimental Medicine, Vol:205, ISSN:0022-1007, Pages:63-77
et al., 2010, Failure to Detect the Novel Retrovirus XMRV in Chronic Fatigue Syndrome, PLOS One, Vol:5, ISSN:1932-6203, Pages:e8519-e8519